Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Public ClinicalTrials.gov record NCT07397338. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors
Study identification
- NCT ID
- NCT07397338
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Enrollment
- 370 participants
Conditions and interventions
Conditions
Interventions
- Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) Drug
- Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) Drug
- Daraxonrasib Drug
- Daraxonrasib (Cohort B1 only) Drug
- Elironrasib Drug
- Ivonescimab Drug
- Zoldonrasib Drug
- cetuximab (Cohort C2 Only) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 29, 2026
- Primary completion
- Apr 30, 2029
- Completion
- Apr 30, 2029
- Last update posted
- May 5, 2026
2026 – 2029
United States locations
- U.S. sites
- 5
- U.S. states
- 4
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Eastern Connecticut Hematology and Oncology Associates | Norwich | Connecticut | 06360 | Recruiting |
| Tennessee Oncology | Nashville | Tennessee | 37023 | Recruiting |
| NEXT Dallas | Irving | Texas | 75039 | Recruiting |
| NEXT Oncology | San Antonio | Texas | 78229 | Recruiting |
| NEXT Virginia | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07397338, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 5, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07397338 live on ClinicalTrials.gov.